Treatment with an antibody that is the mouse equivalent of bapineuzumab (Janssen Pharmaceuticals Inc. / Pfizer Inc.) not only failed to reduce the neuronal hyperactivity that is a physiological feature of Alzheimer's disease (AD), but actually worsened it.